Figure 4

Dynamics of RIPA after initiation of ibrutinib therapy in CLL patients. Consecutive measurements were available in 11 CLL patients and showed a marked decrease (median 17 U, range: 3–70 U vs median 9 U, range: 0–19 U, P=0.019) after a median period of 13 days of ibrutinib therapy.